FXR-Targeted DUBTAC Compound Data for Cholestasis Therapy

Encompassing information on 31 novel compounds designed as FXR-targeted DUBTAC stabilizers for cholestasis therapy. It includes data related to the lead compound D11, its synthesis, and its effects on FXR protein levels in HepG2 cells and mouse models of ANIT-induced cholestasis. The dataset is 4.8 KB in size.

Use Cases

• Analyze the relationship between compound linker design and FXR protein stabilization in HepG2 cells.
• Compare the hepatoprotective efficacy of the 31 synthesized compounds against cholestasis.
• Model the dose- and time-dependent effects of the lead compound D11 on FXR protein levels.
• Evaluate the safety profile data for the DUBTAC stabilizer D11 in cholestasis therapy models.

Strengths

• Data is derived from a study that designed and synthesized 31 novel compounds.
• Includes experimental results from both in vitro (HepG2 cells) and in vivo (mouse model) studies.
• The dataset is associated with a specific, novel therapeutic approach (FXR DUBTAC stabilization).

Limitations

• The dataset is very small at 4.8 KB, indicating limited scope and likely a summary of key results rather than raw experimental data.
• The specific columns, sample data, and row count are unknown, limiting direct analytical utility.
• Data is focused on a specific preclinical research context, which may limit generalizability.

Provenance

Source

figshare, authored by Ming Cui.

Collection Method

Data originates from a research study involving compound design, synthesis, and biological testing.

Freshness

Last updated on 2026-03-20.